Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Monday, Marketbeat.com reports.
A number of other research analysts have also weighed in on the company. Royal Bank of Canada began coverage on Cidara Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $34.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Cidara Therapeutics in a report on Monday, November 11th. WBB Securities lifted their price objective on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 5th. Guggenheim started coverage on shares of Cidara Therapeutics in a research note on Friday, November 8th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, StockNews.com downgraded shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Cidara Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.20.
View Our Latest Stock Analysis on Cidara Therapeutics
Cidara Therapeutics Price Performance
Hedge Funds Weigh In On Cidara Therapeutics
Several institutional investors have recently made changes to their positions in CDTX. Checkpoint Capital L.P. grew its position in Cidara Therapeutics by 25.5% during the third quarter. Checkpoint Capital L.P. now owns 182,426 shares of the biotechnology company’s stock valued at $1,961,000 after buying an additional 37,009 shares during the period. RA Capital Management L.P. purchased a new stake in shares of Cidara Therapeutics during the 3rd quarter worth about $7,558,000. Finally, Geode Capital Management LLC grew its position in shares of Cidara Therapeutics by 22.7% during the 3rd quarter. Geode Capital Management LLC now owns 52,898 shares of the biotechnology company’s stock valued at $569,000 after acquiring an additional 9,771 shares during the period. 35.82% of the stock is owned by hedge funds and other institutional investors.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Read More
- Five stocks we like better than Cidara Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Why Are Stock Sectors Important to Successful Investing?
- What Does the Future Hold for Eli Lilly?
- What is the Hang Seng index?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.